Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease
(GVHD) from maternal or collateral donors was significantly higher than that from other kins.
To reduce the GVHD incidence from maternal or collateral donors, post-transplantation
cyclophosphamide is planned to be added into the protocol in "beijing model".